

molecule having a sequence selected from the group consisting of SEQ ID NOs: 100, 147, 153, 161, 180, 199, 232 and complements thereof.

C1
cont
11. (Twice Amended) The isolated nucleic acid molecule, according to claim 10, wherein said isolated nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 100, SEQ ID NO: 147, SEQ ID NO: 153, SEQ ID NO: 161, SEQ ID NO: 180, SEQ ID NO: 199, and SEQ ID NO: 232.

12. (Twice Amended) An isolated nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1.

2 Sub
C1 D13
16. (Twice Amended) An isolated nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 158 or complement thereof.

Remarks

I. Status of the Claims

Claims 1, 2 and 26 have been cancelled without prejudice to or disclaimer of the underlying subject matter. Claims 10-12 and 16 have been amended. Following entry of the foregoing amendments, claims 10-18 and 20-25 will be pending in the application. Support for the amended claims may be found throughout the specification and in the original claims. No new matter is added by these amendments.

The present Amendment clarifies issues on appeal and does not present new matter. Further, it is submitted that the present Amendment does not raise new issues requiring further search and consideration by the Examiner. As such, entry of the foregoing amendments is respectfully requested.